Authors: Fichtenbaum, CJ Zackin, R Feinberg, J

Citation: Cj. Fichtenbaum et al., Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis forcryptosporidiosis' by Holmberg and Moorman, AIDS, 15(13), 2001, pp. 1745-1745

Authors: Justice, AC Chang, CH Rabeneck, L Zackin, R

Citation: Ac. Justice et al., Clinical importance of provider-reported HIV symptoms compared with patient-report, MED CARE, 39(4), 2001, pp. 397-408

Authors: Dube, MP Sprecher, D Henry, WK Aberg, JA Torriani, FJ Hodis, HN Schouten, J Levin, J Myers, G Zackin, R Nevin, T Currier, JS

Citation: Mp. Dube et al., Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group, CLIN INF D, 31(5), 2000, pp. 1216-1224

Authors: Fichtenbaum, CJ Zackin, R Rajicic, N Powderly, WG Wheat, LJ Zingman, BS

Citation: Cj. Fichtenbaum et al., Amphotericin B oral suspension for fluconazole-refractory oral candidiasisin persons with HIV infection, AIDS, 14(7), 2000, pp. 845-852

Authors: Fichtenbaum, CJ Zackin, R Feinberg, J Benson, C Griffiths, JK

Citation: Cj. Fichtenbaum et al., Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection, AIDS, 14(18), 2000, pp. 2889-2893